1. Home
  2. RAIL vs PYXS Comparison

RAIL vs PYXS Comparison

Compare RAIL & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FreightCar America Inc.

RAIL

FreightCar America Inc.

HOLD

Current Price

$7.69

Market Cap

149.9M

Sector

Industrials

ML Signal

HOLD

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$1.78

Market Cap

124.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAIL
PYXS
Founded
1901
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Railroads
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
149.9M
124.2M
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
RAIL
PYXS
Price
$7.69
$1.78
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
136.4K
708.4K
Earning Date
05-04-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
134.94
3.03
EPS
1.15
N/A
Revenue
$500,991,000.00
$13,858,000.00
Revenue This Year
$6.54
N/A
Revenue Next Year
$30.90
$7,043.98
P/E Ratio
$6.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.27
$0.97
52 Week High
$14.90
$5.55

Technical Indicators

Market Signals
Indicator
RAIL
PYXS
Relative Strength Index (RSI) 39.90 44.93
Support Level $7.58 $1.23
Resistance Level $10.18 $2.27
Average True Range (ATR) 0.31 0.26
MACD 0.02 -0.08
Stochastic Oscillator 14.29 15.45

Price Performance

Historical Comparison
RAIL
PYXS

About RAIL FreightCar America Inc.

FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: